ReviewFrontiers in neurology2025
Peripheral blood immune inflammatory markers in neuromyelitis optica spectrum disorders.
Review in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Integrated Blood Inflammatory Ratios and Cerebrospinal Fluid Blood‒Brain Barrier Dysfunction Predict Relapse Risk in Neuromyelitis Optica Spectrum Disorder.Brain and behavior · 2026Article
- C-Reactive Protein and Neurological Autoimmune Diseases: Bridging the Diagnostic and Pathogenic Gap.International journal of molecular sciences · 2026Review
- Risk of Peripheral Artery Disease and Venous Thromboembolism in Patients with Neuromyelitis Optic Spectrum Disorder: A Nationwide Population-Based Cohort Study.International journal of medical sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune neuroinflammatory disease with high relapse risk and cumulative neurological disability. Identifying, providing early warning, and reproducible monitoring of disease progression and therapeutic efficacy in peripheral blood biomarkers is crucial for clinical management and personalized treatment. Numerous studies have investigated the relationship between peripheral blood immune-inflammatory markers including cytological ratios, cytokines, complement components and NMOSD disease activity, relapse risk, and long-term outcomes, aiming to evaluate their potential application in clinical prognostic assessment and treatment monitoring. Meta-analyses have shown that the neutrophil-to-lymphocyte ratio (NLR) is significantly elevated in patients with NMOSD compared with healthy controls (mean difference (MD) approximately 1.04, 95% CI 0.76-1.32; high heterogeneity). The NLR is associated with relapse risk and disability (EDSS ≥4) (OR for relapse, approximately 1.33-2.14; OR for EDSS ≥ 4, approximately 1.23-1.43), supporting the potential clinical application of peripheral blood Immune inflammatory markers in NMOSD. This review summarizes the current evidence for peripheral blood inflammatory markers in NMOSD, focusing on their clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.